CSR&D Research Career Development Transition Award Application

企业社会责任

• 批准号: 10651692
• 负责人: Gihyun Yoon
• 金额: --
• 依托单位: VA CONNECTICUT HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10651692
• 关键词: Alcohol consumption; Applications Grants; Area; Attention; Award; Biometry; Buprenorphine; Clinical; Clinical Research; Clinical Trials; Cognitive remediation; Collaborations; Communities; Data; Disease; Eszopiclone; Excitatory Amino Acid Antagonists; Funding; Goals; Growth and Development function; High Prevalence; Human; Injectable; Insulin; Intervention; Investments; K-Series Research Career Programs; Ketamine; Lead; Legal patent; Major Depressive Disorder; Mental Depression; Mental Health; Mental disorders; Mission; Morbidity - disease rate; N-Methylaspartate; Naltrexone; Neurosciences; Opioid Antagonist; Opioid Receptor; Paper; Patients; Pharmaceutical Preparations; Pharmacogenomics; Pilot Projects; Policies; Post-Traumatic Stress Disorders; Protocols documentation; Psychiatrist; Publishing; Randomized; Research; Research Activity; Research Methodology; Research Peer Review; Research Personnel; Research Priority; Research Project Grants; Research Technics; Research Training; Risk; Sleeplessness; Substance abuse problem; Suicide prevention; Targeted Research; Testing; Therapeutic; Time; Training Activity; Transition Career Development Award (K22); Translating; Translational Research; Trazodone; United States National Institutes of Health; Universities; Veterans; Wages; addiction; alcohol use disorder; antidepressant effect; clinical care; clinical development; clinical practice; clinical translation; cost; design; donepezil; double-blind placebo controlled trial; drug discovery; effective therapy; gabapentin; innovation; military veteran; mortality; neuroimaging; novel; novel strategies; opioid use disorder; pharmacologic; pre-clinical research; preventive intervention; suicidal

This application is for the Career Development Transition Award (CDTA). As a psychiatrist and clinical researcher, Dr. Yoon has designed and conducted several clinical trials and translational research driven by neuroscience-based hypotheses. The main goal of his research is to evaluate and develop medications for addictive and psychiatric disorders. He is a recipient of the VA Career Development Award (CDA-2) and the Merit Review Award. Dr. Yoon has tested novel approaches for the treatment of addictive and psychiatric disorders, particularly focusing on alcohol use disorder (AUD) and major depressive disorder (MDD). Many of his studies are the first to translate a novel observation in preclinical research to human therapy for these disorders. Addictive and psychiatric disorders produce enormous morbidity and mortality, and are very costly to the VA. The pharmacological approach he is testing has enormous potential to help patients suffering from addictive and psychiatric disorders. His current Merit Review award project is being conducted to evaluate whether the combination of ketamine (NMDA glutamate receptor antagonist) and naltrexone (opioid receptor antagonist) is effective in reducing depression and alcohol consumption. This study is highly innovative by asking important questions on (a) whether opioid receptor stimulation contributes to the antidepressant effects of ketamine and (b) whether the combination of naltrexone and ketamine might be a strategy to reduce addiction risk while rapidly treating depression. Since adequate treatment of MDD and AUD is of major clinical importance, the ketamine plus naltrexone approach may have a transformative impact on patients suffering from this condition. The CDTA will extend his capabilities beyond the current Merit Review Award project and lead his growth and development as a clinical researcher. His research plans during the CDTA period include: (a) conduct of six clinical trials that are currently funded (Project 1-6), (b) resubmission of two NIH R01 applications (Project 7-8), and (c) submission of two new grant applications (Project 9-10). Building on the findings from these projects, his long-term goal is to develop new and more effective pharmacological interventions for addictive and psychiatric disorders. In addition to these research activities, he will participate in training activities. Dr. Yoon is actively collaborating with VA and Yale researchers. They have collected data, shared research techniques, published papers, and submitted grant applications. There are three objectives. Aim #1: To conduct six clinical trials that are currently funded (Project 1-6). Aim #2: To resubmit two NIH R01 applications (Project 7-8) and submit two new grant applications (Project 9- 10) Aim #3: To participate in training activities in (1) ketamine and psychiatric research, (2) neuroscience and drug discovery, (3) addiction research, (4) clinical trials and research methodology, (5) neuroimaging, (6) pharmacogenomics, and (7) biostatistics. Conclusion: The CDTA will protect Dr. Yoon’s research training and activity to develop more effective treatments for addictive and psychiatric disorders.

这是职业发展转型奖（CDTA）的申请。作为精神科医生和临床医生